TSX symbol: SBS
CALGARY, March 14 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that Arcadia Biosciences, Inc., made an important step forward in the commercialization of High GLA Safflower Oil. Arcadia entered into an exclusive global alliance with Bioriginal Food and Science Corp., to market and distribute High GLA Safflower Oil, an omega-6 polyunsaturated fatty acid with proven heath benefits, as a nutritional supplement and food ingredient. SemBioSys was contracted by Arcadia to utilize Arcadia's proprietary genes and SemBioSys' promoters and safflower transformation technology to produce and deliver safflower seed lines containing more than 40 percent GLA. Under the agreement, SemBioSys receives milestone payments upon the successful scale-up of GLA safflower lines as well as royalties from commercial sales.
GLA (gamma linolenic acid) is an omega-6 polyunsaturated fatty acid which, along with omega-3 fatty acids, has demonstrated health benefits. GLA's clinically-validated benefits include anti-inflammatory effects and improved skin health and appearance. Existing commercial sources of GLA, evening primrose oil and borage oil, contain 10 or 20-23 percent GLA, respectively. With a GLA content of 40 percent, Arcadia's high-GLA safflower oil would significantly reduce the daily consumption of GLA oil capsules and make it more convenient and affordable for consumers. According to ICIS Chemical Business Americas, the U.S. market for GLA oils is currently valued at more than US$100 million. With a more convenient, more highly concentrated source of GLA, Arcadia believes the market can grow beyond this figure.
"Nutritional supplements and nutraceuticals are a growing market as
health conscious consumers are increasingly choosing to augment their diet
with nutrients that ha
|SOURCE SemBioSys Genetics Inc.|
Copyright©2008 PR Newswire.
All rights reserved